Pfizer-BioNTech COVID-19 Vaccine

On November 9, 2020 New York-based Pfizer and the German company BioNTech made history by indicating that their coronavirus vaccine was over 90 percent effective. It was the first time anyone had found such evidence. Just over a month later, on December 11, 2020, the Food and Drug Administration (FDA) granted it the first emergency use authorization ever given by the United States to a coronavirus vaccine.

The first vaccinations approved by the U.S. government to protect against coronavirus were administered on Monday, December 14 2020. Healthcare workers in New York were among the first to receive the Pfizer-BioNTech vaccine. Pfizer is expected to supply the US with 100 million doses of the COVID-19 vaccine, bringing the total to 200 million doses to be delivered by July 31, 2021.

Today, January 11, 2021, BioNTech now aims to produce 2 billion doses of its Covid-19 vaccine with Pfizer this year. BioNTech previously said it aimed to produce 1.3 billion doses in 2021. The update comes as U.S. officials race to distribute as many vaccine doses as possible. As of Friday, January 8, 2021, the U.S. has distributed more than 22.1 million doses of vaccine, but just over 6.6 million have been administered, according to the Centers for Disease Control and Prevention.